Incyte, a renowned biopharmaceutical company, has reportedly announced the first presentation of Phase 3 data for ruxolitinib cream at the RAD (Revolutionizing Atopic Dermatitis) conference. The Phase 3 TRuE-AD program, including the TRuE-AD2 and TRuE-AD1 studies, is assessing ruxolitinib cream 0.75% as well as 1.5% twice daily for the treatment of people who are suffering from mild to moderate atopic dermatitis.
Jim Lee, Group VP, Inflammation & Autoimmunity, Incyte, stated that the data would be presented during the virtual RAD conference, showing that ruxolitinib cream has substantially reduced both the itch and skin inflammation linked with atopic dermatitis. The decrease in itch could possibly improve outcomes that are key disease, and quality of life-related among patients living with atopic dermatitis.
Lee further stated that the company is thrilled to share key data with the dermatology community since they bolster the capability of ruxolitinib cream to turn into a significant anti-inflammatory and antipruritic treatment alternative for patients with atopic dermatitis. The company is looking forward to presenting an NDA (New Drug Application) to the Food and Drug Administration of the U.S. by the end of the year.
The total safety profile of ruxolitinib cream in atopic dermatitis was in consistence with past study data, with no new safety signals detected. The long-term safety of ruxolitinib cream is currently being assessed inside the 44-week extension time of the two studies.
Kim Papp, Coordinating Investigator, TRuE-AD program, and President and Founder, Probity Medical Research, stated that atomic dermatitis can profoundly affect patients and their quality of life as well. There is a requirement for more treatment alternatives that could further improve the itch and other such symptoms leading to interruption in activities of everyday living. The capability of ruxolitinib cream to become an essential option for treatment of patients living with atopic dermatitis is thrilling.